New cell sources for CAR-based immunotherapy

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazinani, Marzieh, Rahbarizadeh, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163725/
https://www.ncbi.nlm.nih.gov/pubmed/37147740
http://dx.doi.org/10.1186/s40364-023-00482-9
_version_ 1785037942961471488
author Mazinani, Marzieh
Rahbarizadeh, Fatemeh
author_facet Mazinani, Marzieh
Rahbarizadeh, Fatemeh
author_sort Mazinani, Marzieh
collection PubMed
description Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Despite impressive clinical outcomes, concerns about treatment failure associated with low efficacy or high cytotoxicity of CAR-T cells remain. While the main focus has been on improving CAR-T cells, exploring alternative cellular sources for CAR generation has garnered growing interest. In the current review, we comprehensively evaluated other cell sources rather than conventional T cells for CAR generation.
format Online
Article
Text
id pubmed-10163725
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101637252023-05-07 New cell sources for CAR-based immunotherapy Mazinani, Marzieh Rahbarizadeh, Fatemeh Biomark Res Review Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Despite impressive clinical outcomes, concerns about treatment failure associated with low efficacy or high cytotoxicity of CAR-T cells remain. While the main focus has been on improving CAR-T cells, exploring alternative cellular sources for CAR generation has garnered growing interest. In the current review, we comprehensively evaluated other cell sources rather than conventional T cells for CAR generation. BioMed Central 2023-05-06 /pmc/articles/PMC10163725/ /pubmed/37147740 http://dx.doi.org/10.1186/s40364-023-00482-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Mazinani, Marzieh
Rahbarizadeh, Fatemeh
New cell sources for CAR-based immunotherapy
title New cell sources for CAR-based immunotherapy
title_full New cell sources for CAR-based immunotherapy
title_fullStr New cell sources for CAR-based immunotherapy
title_full_unstemmed New cell sources for CAR-based immunotherapy
title_short New cell sources for CAR-based immunotherapy
title_sort new cell sources for car-based immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163725/
https://www.ncbi.nlm.nih.gov/pubmed/37147740
http://dx.doi.org/10.1186/s40364-023-00482-9
work_keys_str_mv AT mazinanimarzieh newcellsourcesforcarbasedimmunotherapy
AT rahbarizadehfatemeh newcellsourcesforcarbasedimmunotherapy

Ejemplares similares